We urge you to utilize Edwards Lifesciences fundamental analysis to see if markets are presently mispricing the company. In plain English you can exercise it to find out if Edwards Lifesciences is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. . We found thirty-five available fundamental indicators for Edwards Lifesciences Corporation which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all Edwards Lifesciences fundamentals including its EBITDA, Earnings Per Share, Z Score, as well as the relationship between Debt to Equity and Total Asset . Given that Edwards Lifesciences has Price to Earning of 35.5 times, we urge you verify Edwards Lifesciences Corporation prevailing market performance to make sure the company can sustain itself down the road.Use Edwards Lifesciences to enhance returns of your portfolios. The stock experiences normal upward fluctuation. Check odds of Edwards Lifesciences to be traded at $130.74 in 30 days
Edwards Lifesciences Valuation Over Time
Edwards Lifesciences Company SummaryEdwards Lifesciences competes with Express Scripts, AmerisourceBergen, Baxter International, and BECTON DICKINSON. It offers transcatheter heart valve therapy solutions comprising transcatheter aortic heart valves and their delivery systems for the nonsurgical replacement of heart valves. Edwards Lifesciences Corp also offer surgical heart valve therapy products, such as pericardial valves for aortic and mitral replacement, and minimally invasive aortic heart valve system and tissue heart valves and repair products, which are used to replace or repair a patients diseased or defective heart valve. In addition, it produces pericardial valves from biologically inert animal tissue and offer heart valve repair therapies, including annuloplasty rings and systems. Further, Edwards Lifesciences Corp offers critical care products, such as hemodynamic monitoring systems to measure a patients heart function in surgical and intensive care settings pulmonary artery catheters and continuous venous oximetry catheter for measuring central venous oxygen saturation. Additionally, its critical care solutions include disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection and peripheral vascular solutions used to treat endolumenal occlusive disease, such as embolectomy catheters for removing blood clots from peripheral blood vessels. Edwards Lifesciences Corp distributes its solutions through direct sales force and independent distributors. Edwards Lifesciences Corporationration was founded in 1999 and is headquartered in Irvine, California.
Edwards Lifesciences Total Asset vs Current Liabilities
Edwards Lifesciences Corporation is rated below average in total asset category among related companies. It is rated below average in current liabilities category among related companies creating about 0.12 of Current Liabilities per Total Asset. The ratio of Total Asset to Current Liabilities for Edwards Lifesciences Corporation is roughly 8.52